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Abstract 
Purpose: Several prognostic signatures for early ER+ breast cancer have been established with a 10-
year follow-up. We tested the hypothesis that signatures optimised for 0-5 year and 5-10 year 
follow-up separately are more prognostic than a single signature optimised for 10 years.  
Experimental Design: Genes previously identified as prognostic or associated with endocrine 
resistance were tested in silico using Cox regression in 747 ER+/HER2- samples from postmenopausal 
patients treated with 5 years’ endocrine therapy. RNA expression of genes found to be significant 
was assayed in primary ER+/HER2- tumours from 948 postmenopausal patients treated with 5 years’ 
anastrozole or tamoxifen in the TransATAC cohort. Prognostic signatures for 0-10, 0-5 and 5-10 years 
were derived using Elastic Net modelling. Signature comparison was performed with Cox regression 
and likelihood ratio statistics. Validation was by a case:control (POLAR) study in 422 samples derived 
from a cohort of 1449.  
Results: Ninety-three genes were selected by the in silico modelling; 63 of these were significantly 
prognostic in TransATAC, most similarly across each time period. Contrary to our hypothesis, the 
derived early and late signatures were not significantly more prognostic than the 10-year signature. 
The 10-year signature was validated in the POLAR case:control set and showed similar prognostic 
information to OncotypeDX, PAM-50 ROR, Breast Cancer Index and IHC4 in TransATAC. 
Conclusions: The derived 10-year signature predicts risk of metastasis in patients with ER+/HER2- 
breast cancer similar to commercial signatures. The hypothesis that early and late prognostic 
signatures are significantly more informative than a single signature was rejected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Introduction 
Five years of adjuvant endocrine therapy is standard treatment for patients with primary oestrogen 
receptor positive (ER+) breast cancer, and clearly improves prognosis (1). Multiparameter molecular 
assays are increasingly used to estimate prognosis and guide treatment decisions of patients with 
primary ER+ breast cancer. These include the Oncotype DX Recurrence Score (RS) (2), Prosigna 
PAM50 (3), Breast Cancer Index (BCI) (4), EndoPredict (5) and IHC4 (6). All of them have been 
evaluated in the TransATAC series of samples that were established from patients with ER+ primary 
breast cancer randomised to treatment with 5 years’ anastrozole or tamoxifen in the ATAC trial (7).  
It has become clear that following surgery the risk of recurrence in ER+ primary breast cancer is not 
constant across all breast cancer subtypes, as evident between intrinsic subtypes. For example, data 
from 2985 tumours showed basal subtypes experiencing high recurrence rates early that decline 
after 5 years after surgery, contrary to patients categorised as luminal A, who experienced a lower 
but relatively constant recurrence rate during the first decade (8). 
There are additional molecular differences beyond the subtype of a tumour. In TransATAC we have 
previously shown that the oestrogen-module of RS was prognostic within five years of surgery 
(during endocrine therapy), however it became non-informative for recurrences beyond five years 
thus weakening the overall prognostic value of RS (9). In the same data set, patients with high ER 
expression by RT-PCR were twice as more likely to have a relapse 5-10 years after surgery than 
within the first 5 years. Bianchini et.al. reported risk stratification by integrating the mitotic kinase 
score (MKS) and an ER-related score (ERS), both based on genes constituting the proliferation and 
oestrogen modules of RS. Women with high MKS and ERS tumours were at greater risk of late 
recurrence (10). More recently, improved risk estimation beyond 5 years by RS was reported when 
integrated with dichotomised ER expression assessed by RT-PCR (11). 
Extending endocrine therapy beyond five years has been shown to reduce late recurrence rate (12, 
13), however those most likely to benefit from such therapy need to be identified. While some of 
the widely used prognostic assays for ER+ patients have been shown to be prognostic for risk beyond 
five years (14-17), none of them have been optimised to quantify residual risk after five years free 
from recurrence and their ability to predict late relapse varies substantially (18). The different time-
dependent performance of multiparameter molecular signatures indicates that molecular features 
of ER+ breast cancers may be identified to improve prediction of residual risk in order to spare those 
patients with significantly low low risk of late recurrence from extended endocrine therapy.  
We therefore hypothesised that prognostic signatures optimised specifically for the early (0-5 years) 
and late (5-10 years) follow-up periods respectively would be more prognostic than a single 
signature optimised for the whole 10-year follow-up period. To test this hypothesis we developed 
time-dependent prognostic signatures in patient samples from the TransATAC series for early, late 
and 10 year follow-up periods. The prognostic performance was tested in an independent sample 
set and against commercial signatures already assessed in TransATAC. Our primary aim was to 
compare the prognostic value of the newly developed signature(s) added to clinical treatment score 
(CTS) (6) and that of PAM50 ROR-P added to CTS. 
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Materials and methods 
Patient cohorts 
An in silico analysis drew on four published breast cancer cohorts (GSE6532, GSE9195, GSE17705, 
GSE26971) analysed on either Affymetrix HG-U133A (GPL96) or HG-U133 Plus 2.0 (GPL570) 
microarray platforms. The two platforms shared 22,277 probes to which we restricted our analyses. 
This cohort had 747 unique patient samples that matched our selection criteria: ER+, HER2-, treated 
with five years of endocrine therapy, chemotherapy naive, with either distant metastasis-free 
survival (DMFS) or relapse-free survival (RFS) available with a long follow-up. Details of the inclusion 
criteria are listed in Supplementary Methods and a full list of samples included in the analysis is 
shown in Supplementary Table S1. 
In the TransATAC cohort, RNA was available from 948 formalin-fixed paraffin-embedded (FFPE) 
tumours from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, previously extracted 
by Genomic Health Inc. (GHI) (19). Eligibility required hormone receptor (HR)+, HER2- disease, 
without chemotherapy treatment and at least 500ng RNA available. One hundred and eighty three 
recurrence events were recorded for this cohort. This study was approved by the South-East London 
Research Ethics Committee and all patients gave informed consent.  
The POLAR (Predictors Of early versus LAte Recurrence in ER+ breast cancer) samples were identified 
from archives of The Royal Marsden Hospital (RMH), London, United Kingdom and Lund University 
Hospital (LUH) Biobank, Sweden. Eligibility criteria were patient with ER+, HER2- early breast cancer 
diagnosed between January 2000 and December 2004, treated with curative intent and with a 
follow-up data cut-off at May 2014. Patients must have received five years of adjuvant endocrine 
therapy (unless relapse occurred within this time); (neo)adjuvant chemotherapy was permitted. A 
422 sample case:control design was used; controls were randomly selected according to matching 
criteria from the remaining cohort of patients who did not relapse during follow-up. The total 
number of patients that was drawn upon was 1449. The four matching criteria used in this study 
were: 1) age at diagnosis (<50 or >50 years), 2) NPI category (<3.4; 3.4-5.4, >5.4), 3) type of adjuvant 
endocrine therapy (tamoxifen only vs. any aromatase inhibitor (AI)) and 4) chemotherapy use (yes or 
no). Two-hundred and forty-seven recurrence events were recorded. The POLAR study was 
approved by the RMH Research Ethics Committee (CCR: 4122) and the ethics committee of Lund 
University Hospital (LU 240-01). 
Study end points 
The primary endpoint was time to any recurrence that was defined as either locoregional (ipsilateral 
breast, contralateral breast and regional lymph nodes) and/or distant recurrence. Secondary 
endpoint was time to distant recurrence, which was the time from diagnosis until metastasis from 
the primary tumour at distant organs, excluding contralateral disease and locoregional and 
ipsilateral recurrences. Death before recurrence was treated as a censoring event for both 
endpoints. 
 
Analytic procedures 
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In the in silico data set 454 probes representing 454 genes (Supplementary table 3) were analysed at 
univariate level; those significant in univariate analyses in a particular setting were entered into 
multivariate analyses. Additional details are in the Supplementary Methods. 
For TransATAC, RNA was extracted by GHI for the RS study (19). One-hundred ng RNA was used with 
the nCounter platform (NanoString Technologies, Seattle, WA) to assay the 93 endogenous and 7 
reference genes selected in the process of the in silico analysis in 948 TransATAC samples.  
For POLAR, RNA was extracted from three 3x10micron unstained sections with more than 40% 
tumour cellularity using RNeasy FFPE kit (Qiagen) according to the manufacturer’s instructions. RNA 
was quantified by Nanodrop (Thermo Fisher Scientific). Between 50 and 200ng RNA was used to 
profile the expression of 27 endogenous and 5 reference genes with the NanoString nCounter.  
NanoString expression data was background corrected by subtracting the mean of the eight negative 
control probes, normalised with the geometric mean of five reference genes that had a correlation 
of Pearson’s r>0.8 with all endogenous genes. The data set was then log (base 2)-transformed and z-
score transformed. KIF20A gene was detected in <10% of samples in the TransATAC cohort and was 
removed from the data set. CTS, which carries information on tumour size, nodal status, grade, age 
and type of endocrine therapy was calculated as published previously (6). 
We trained separate early, late and 10-year signatures by performing elastic net analysis in the 
TransATAC training cohort. Our objective was to test if the early and late signatures had statistically 
significantly more prognostic power than the 10-year signature. If so, we would test the validity of 
the early and late signatures in the non-chemotherapy-treated subpopulation of POLAR and also test 
their performance in the chemotherapy-treated POLAR cohort. If the early and late signatures were 
not statistically significantly more prognostic than the overall signature, we would test the validity of 
the overall signature in the chemotherapy-naïve POLAR group and explore its performance in the 
chemotherapy-treated POLAR group. 
Statistical analyses in the in silico cohort were carried out at the ICR using R version 3.03. Statistical 
analyses using the TransATAC cohort were performed at Queen Mary University of London with 
STATA version 13.1 and R version 3.0.3. Statistical work on POLAR was carried out at the Royal 
Marsden Hospital using the Statistical Analysis Plan version 2.0 and PRISM 6.0c. The statistical 
analysis plan for the TransATAC study was approved by the Long-term Anastrozole vs Tamoxifen 
Treatment Effects (LATTE) committee and for the POLAR study by the RMH Committee for Clinical 
Research before data analysis took place and is described in the Supplementary Methods. All 
statistical tests were two-sided. 
 
Results 
Candidate gene selection and in silico analysis 
In order to derive time-dependent prognostic signatures we shortlisted 585 candidate genes 
representing proliferation, oestrogen signalling, immune infiltration and immune signalling. These 
genes were tested for prognostic significance in silico from publically available gene expression sets 
in ER+ endocrine treated breast cancer. A flow-chart illustrating the approach is shown in Figure 1. 
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Sixty-seven genes of interest that are part of the PAM50, OncotypeDX RS, EndoPredict and BCI 
profilers were also included. Additional genes likely to be related to benefit from endocrine therapy 
were identified from 81 patients by reanalysing our previously published neoadjuvant endocrine 
therapy treated set of samples (20) (https://www.synapse.org/#!Synapse:syn16243). From this 
dataset we identified 164 candidate genes by examining correlation of individual gene expression 
from untreated biopsies with change in: 1) Ki67, 2) proliferation-associated gene cluster, 3) 
oestrogen-associated gene cluster, 4) expression of mGIDE (modified version of the Global Index of 
Dependence on Estrogen) (21) genes following two weeks of AI treatment. An additional 354 genes 
were selected based on literature searches. Genes from published gene modules of the 
proliferation-associated gene cluster, oestrogen-associated gene cluster and inflammatory response 
signature (20), the tumour invasion/metastasis module (PLAU) (22) and IGG-14 module 
(immunoglobulin gamma) (23) were also included. The complete list of candidate genes and the 
reason for their inclusion is detailed in Supplementary Table 1. 
Seven hundred and fourty-seven samples from microarray expression dataset was compiled from 
four publically available breast cancer cohorts to investigate the relationship between genes and 
outcome (Supplementary table 2) (5, 24-26). Expression data was available for 454 genes 
(Supplementary table 3). We performed univariate Cox proportional hazards regression analyses for 
early, late and 10-year follow-up periods using relapse-free survival (RFS) and distant metastasis-free 
survival (DMFS) as end-points respectively that identified 212 genes that were significant at p<0.01 
in any of the analyses (Supplementary Table 4). Genes significantly prognostic in a particular time-
period were taken forward for multivariate analyses performed by Cox proportional hazards 
regression with DMFS and RFS as endpoints respectively in the early, late and 10-year follow-up 
settings. This resulted in 88 genes being selected in the models (Supplementary Table 5), of which 17 
genes were removed due to high correlation of expression with other candidates already selected 
(Supplementary Table 6). An additional 29 genes were added that included candidates without 
probes available in the in silico analyses, some recently emerging candidates and also seven 
reference genes (Supplementary Table 7).  
Expression profiling and signature building in TransATAC 
Sample availability in TransATAC is shown in Figure 2a. Expression data for the 100 selected genes 
(including housekeeping genes; Supplementary Table 9) were obtained for 948 patient samples in 
TransATAC using the NanoString nCounter. We assessed the prognostic value of these molecular 
variables in TransATAC for early, late and 10-year time periods for RFS. Sixty-three genes were 
statistically significant in at least one of the time-windows assessed (Supplementary Figure 1, 
Supplementary Table 7). We found different prognostic properties between early and late periods 
for 20 genes. Six genes were prognostic early but not in the late period (CD79, IL6ST, LRRC48, 
MPZL1, PGR, PIGV); 14 genes were not significantly prognostic early but gained prognostic 
significance in the late setting (ANP32E, ANXA1, CTSL2, EPB41L2, ESR1, FOXA1, ICOS, IL17RB, MMP9, 
MYCBP2, NR2F1, PDZK1, SLAMF8 and TCF7L2).  
The TransATAC cohort was then randomly split into 2/3 (n=634) training and 1/3 (n=314) validation 
sets while ensuring that the recurrence rate was similar in the two subgroups. Demographics for the 
training, validation and overall cohorts are presented in Supplementary Table 10. We aimed to select 
prognostic variables independent of clinico-pathological features that are commonly used for 
7 
 
prognosis. To achieve this, on top of the 63 statistically significant genes in univariate analyses, CTS 
was also entered into multivariate selections for early, late and 10-year time-periods respectively. 
Elastic Net Penalised Cox regression with leave one out cross-validation was used for feature 
selection in the TransATAC training set. CTS was selected in all three signatures in addition to 18 
genes in the 10-year, 16 genes in the early and 15 genes in the late follow-up analyses. The variables 
and their coefficients derived from the elastic net models are listed in Table 1. CTS had the highest 
coefficient in each of the time periods. 
Comparison of time period-optimised prognostic signatures in TransATAC validation set 
TransATAC was used to validate and compare the prognostic information of the three time period-
dependent signatures (Table 2). In the 0-10 years follow-up period all three newly derived signatures 
were significantly prognostic, with the late signature being significantly less informative than the 10-
year signature (10-year signature LRχ2=28.0; early signature LRχ2=33.4; late signature LRχ2=18.1). In 
the 0-5 years period the 10-year signature and early signature were equally prognostic and 
significantly more than the late signature (LRχ2: 10-year signature=14.1; LRχ2: early signature=14.9; 
LRχ2: late signature=8.9). In the late setting the early signature was the most prognostic, followed by 
the 10-year and late signatures (LRχ2: 10-year signature=13.9; LRχ2: early signature=18.6; LRχ2: late 
signature = 9.3). CTS was strongly prognostic in all three time periods (CTS 0-10y LRχ2=48.7; CTS 0-5y 
LRχ2=29; CTS 5-10y LRχ2=19.8).  
For the 0-10 year period all three signatures added statistically significant prognostic information 
beyond that of the CTS (ΔLRχ2: 10-year signature=7.9; ΔLRχ2: early signature=10.3; ΔLRχ2: late 
signature=4.3). In the 0-5 years period none of the signatures added significant prognostic 
information to CTS. However in the 5-10 yeard period the 10-year and early signatures added 
statistically significant prognostic information to CTS (10-year signature ΔLRχ2=4.8; early signature 
ΔLRχ2=8.0; late signature ΔLRχ2=2.7).  
Given that the early- and the late-signatures were not statistically significantly more prognostic than 
the 10-year signature in the respective periods they were optimised for, we rejected our primary 
hypothesis that signatures optimised separately for the early and the late follow-up periods 
respectively are more prognostic than a 10-year signature but we proceeded to assess the validity of 
the 18-gene, 10-year signature in an independent cohort and to compare its performance with that 
of commercial signatures. 
 
Signature test of 10-year validity in POLAR cohort 
A matched case-control set of samples was compiled from the Royal Marsden Hospital and Lund 
University Hospital archives (POLAR) to validate the 10-year signature (Figure 2b, Supplementary 
Table 11). Our aims were to test the validity the 10-year signature in an endocrine-therapy only 
cohort similar to the training set, and also to explore if the prognostic property (if any) extends to a 
higher risk, chemotherapy-treated population. The latter cohort was of interest in the 5-10 year 
period because of the potential for its use in selecting patients for extended adjuvant endocrine 
therapy. 
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Despite having matched cases and controls on NPI category, the CTS was still higher in cases than in 
controls: 201.9+/-98 (SD) vs. 170.8+/-87.6 (p=0.0009) respectively. In a univariate analysis, CTS had 
an Odds Ratio (OR) of 1.004 (95% CI 1.001-1.006) for a one unit increase. We assessed a multivariate 
model with CTS with and the 10-year signature; both were found to be statistically significant: 10-
year signature OR=1.851 (95%CI 1.194-2.868), p=0.006; CTS OR=1.003 (1.001-1.005), p=0.012. 
We also assessed whether the 10-year signature added significant prognostic information above CTS 
alone using likelihood ratio tests (Table 3). In the overall POLAR cohort (n=422), CTS was prognostic 
across 10 years and in the early follow-up period (CTS 0-10 years period LRχ2=11.23; 0-5 years period 
LRχ2=22.09) but not in the 5-10 year period. The 10-year signature was prognostic in all three follow-
up periods and contributed to CTS with significant prognostic information in the 10-year and early 
periods (0-10 years period ΔLRχ2: CTS+10-year signature vs. CTS=7.74; 0-5 years period ΔLRχ2: 
CTS+10-year signature vs. CTS=7.59) but not in the 5-10 year period. Both CTS and the 10-year 
signature were marginally more informative across the 10 years in the chemotherapy-treated POLAR 
cohort compared with the endocrine only population despite the latter having more patients and 
events (patients: n=170 vs. n=252; events: 99 vs. 148). Additionally, the 10-year signature added 
significantly more prognostic information to CTS in the chemotherapy-treated group (ΔLRχ2: CTS+10-
year signature vs. CTS=6.71) when compared to those receiving endocrine therapy only (ΔLRχ2: 
CTS+10-year signature vs. CTS=2.47). 
Prognostic properties of the 18 individual genes constituting the 10-year signature were assessed in 
POLAR and compared to data obtained in TransATAC. In POLAR only 8 out of the 18 genes were 
significantly prognostic at the univariate level (Supplementary Figure 2) but all genes except tumour 
necrosis factor alpha (TNF) showed the same prognostic direction both in TransATAC and POLAR. 
Comparison of the 10-year signature with CTS, RS, PAM50 ROR, BCI and IHC4 in TransATAC 
We have previously published data on the prognostic performance of CTS, RS, PAM50 ROR, BCI and 
IHC4 in TransATAC (6, 16, 19, 27); data for all scores was available for 271 patients in the validation 
cohort. We assessed their prognostic information for 10 years after surgery using any recurrence 
and distant recurrence as endpoints respectively and compared them with the newly developed 10-
year signature (Table 4). For both any and distant recurrence the BCI provided the most added 
information beyond the CTS in this set (any recurrence: CTS: LRχ²=37.4; BCI: ΔLRχ²=9.5; distant 
recurrence: CTS: LRχ²=46.7; BCI: ΔLRχ²=14.5, respectively). The novel 10-year signature performed 
similarly to the other three scores in this respect. 
 
Discussion 
We developed novel time-specific prognostic signatures for early, late and 10-year follow-up periods 
for ER+, HER2- patients treated with endocrine therapy alone to allow us to test the hypothesis that 
sequentially applying early and late signatures could be more prognostic for risk of relapse than a 
single newly developed 10-year signature. This hypothesis was largely based around our observation 
that the performance of some components in many of the commercially available signatures varied 
between these time periods. For example, we found that ESR1 and the oestrogen module overall in 
the RS was less prognostic in years 5-10 than 0-5 (9). Analogous findings were made by Bianchini et 
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al (10). Very recently the EBCTCG published data on clinicopathological and limited 
immunohistochemical data on over 60,000 women that were treated with 5 years of endocrine 
therapy (28). While progesterone receptor showed strong prognostic performance in years 0-5, it 
showed no significant relationship with prognosis thereafter. These data on markers associated with 
hormone responsiveness support the contention, but by no means prove, that cessation of 
endocrine treatment at 5 years may lead to increased recurrence risk in more hormonally responsive 
tumours. We therefore included in our assessment genes that we and others have found to be 
associated with the antiproliferative response of primary ER+ breast cancer to oestrogen 
deprivation. Our work involved an in silico discovery set of 747 samples, training and test sets of 634 
and 314 TransATAC samples, respectively, and independent case:control series from 1449 eligible 
samples. As such this was one of the largest original gene expression analyses undertaken for 
evaluating prognosis in ER+ breast cancer. 
Of the 92 genes selected from in silico data and assessed in univariate analyses in TransATAC we 
found 63 to be significantly prognostic (P<0.05) in any of the three time periods which is 
considerably more than expected by chance after allowing for multiple testing errors. For most 
genes the same prognostic pattern was observed for early and late periods however we observed 
some possibly different prognostic properties for 20 genes. Notably, consistent with the above 
arguments, higher levels of ESR1 and its pioneer factor FOXA1 showed a shift at 5 years to be 
associated with worse prognosis beyond 5 years but surprisingly over the 10 year period the two 
genes were associated with poor prognosis. The complementary role whereby upon stimulus ER 
binding to chromatin is dependent on the presence of FOXA1 is well established (29). In our dataset 
FOXA1 and ESR1 correlated highly (Pearson’s R: 0.65); the possibility that increased expression of 
one or both may put patients at increased risk of late relapse merits further investigation, 
particularly with regard to whether the genes also identify patients who benefit from extended 
adjuvant therapy. 
The optimised time-dependent signatures derived in the TransATAC training set were rather similar 
to one another in makeup. All genes in the 10-year signature featured in either (or both) of the early 
and late signatures with their coefficients being in the same direction. The early and late signatures 
had five and three variables respectively not present in the 10-year signature suggesting that the 
early and late signatures may not have captured time-specific features or that such time-specific 
features that exist exert a minor modulatory influence on the overall prognosis over 10 years. It is 
notable that CTS was consistently the most prognostic variable in the three time-dependent models 
and that its contribution was similar in both early and late recurrence. This is consistent with the 
data of the EBCTCG that classical clinico-pathologic features retain their strong prognostic influence 
beyond 5 years (28).  
Given that the 10-year signature captured prognostic features of both early and late events, it is 
perhaps not surprising that no improvement was seen in the use of early and late signatures 
compared to the overall 10-year signature that led to the rejection of our hypothesis. Also, it should 
be noted that splitting of the 0-10 year time period into 0-5 and 5-10 year periods markedly reduces 
the power to detect prognostic contributions. At least a contributory factor for the lack of 
improvement may be because of the dominance of proliferation-related genes in our and other 
signatures. As shown in our earlier analysis of the RS, each of the individual proliferation genes and 
the integrated module are equally prognostic before and after 5 years (9). Notably this is also 
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supported by the observation by the EBCTCG that Ki67 was equally prognostic before and after 5 
years in their overview analysis of late recurrence (28). 
The 10-year signature was nonetheless validated in the POLAR sample set and provided significant 
prognostic information in both chemotherapy-naïve and -treated cohorts. Moreover, it added 
independent prognostic information beyond that of CTS in the POLAR cohort. Comparison of the 
information provided by each gene showed that eight out of the 18 genes were significantly 
prognostic at univariate level in POLAR (four genes at P<0.05, two genes at P<0.01 and three genes 
P<0.001). TNF showed opposite prognostic direction in training and validation sets, thus weakening 
the performance of the signature in POLAR. TNF is a versatile pro-inflammatory cytokine that has 
both pro- and anti-tumour activities promoting lymphocytic infiltration, activating the nuclear factor-
κB, c-Jun N-terminal kinase and mitogen-activated protein kinase pathways and is capable of 
inducing apoptosis through TNF receptor 1 and 2 (30). It may be that the inclusion of higher risk, 
chemotherapy-treated patients in POLAR contributed to the difference in TNF’s prognostic pattern; 
further investigation is needed to explain the relationship of TNF and risk of relapse in these cohorts. 
The 10-year signature was compared to established prognostic signatures in the TransATAC 
validation set. Importantly, the 10-year signature was developed for the endpoint of any recurrence 
contrary to the endpoint of distant recurrence used in the development of RS, PAM50 ROR, BCI and 
IHC4. In univariate assessments, BCI and the 10-year signatures were the most informative for both 
all and distant recurrence. When added to CTS, all signatures assessed provided similar amount of 
information, with CTS+BCI being the most informative for distant recurrence. This new signature did 
not outperform the established signatures even though it was based on a large and wide-ranging 
analysis of both established prognostic genes and novel genes with a clear rationale for inclusion. It 
seems unlikely that a step-change in prognostic performance with any further elaborations on gene 
expression profiles in this context; other approaches that assess response to treatment or integrate 
mutational profiles or by the use of circulating tumour DNA (ctDNA) are likely to be more fruitful. 
The results presented here support the mounting evidence that better risk estimation can be 
achieved by combining molecular profilers with clinico-pathological factors. For the three time-
dependent signatures derived in TransATAC CTS was the most prognostic in all three time-
dependent signatures and provided more prognostic information than RS, ROR, BCI and IHC4 
respectively. Additionall, all profilers added significant prognostic information to CTS leading to 
combined signatures being significantly more informative. 
Our study has strengths and limitations. An advantage was that a large discovery cohort of 634 
samples was used for signature training. All tumours were ER+, HER2- from postmenopausal patients 
who had five years of endocrine therapy without chemotherapy. This was a homogeneous group of 
breast cancers which reduced confounding factors such as tumour subtype, differing treatment 
lengths and types. Data for the clinical prognostic tests were obtained by the same methods as set 
out by the tests’ developers. The same batch of RNA was used for the newly developed signatures 
presented here and for the clinical prognostic tests used in the comparisons, reducing intra-sample 
variation. The clinical data were derived from a registration standard trial with comprehensive 
follow-up over 10 years. Limitations include that CTS, IHC4 and the 10-year signature were derived in 
TransATAC therefore their performance in the comparisons was slightly overestimated compared to 
what we would see in independent cohorts. Also, although this study was relatively large compared 
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to others, the splitting of the data into early and late signatures decreased the statistical power for 
comparisons within those time periods. 
In summary, we found that early and late signatures are unlikely to be more informative for 
predicting relapse than a single signature optimised for 10 years. Further development of gene 
expression signatures for prognosis in endocrine-treated ER+ breast cancer patients is unlikely to 
achieve a substantial improvement in performance. 
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BCI, RS, ROR and IHC4 for all and distant recurrences respectively in the TransATAC validation 
cohort. 
ATAC = Arimidex, Tamoxifen, Alone or in Combination; ER = oestrogen receptor; PgR = progesterone 
receptor; RMH = Royal Marsden Hospital; LUH = Lund University Hospital; ET = endocrine Therapy. 
Supplementary Table S1. List of 585 candidate genes 
Supplementary Table S2. List and identifiers for the 747 patient in silico cohort 
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Supplementary Table S3. List of 454  Affymetrix probes studied in silico 
Supplementary Table S4. List of 212 genes significantly prognostic (p<0.01) in any of the three time 
periods studied in silico 
Supplementary Table S5. List of 88 genes by multivariate selections in any of the three time periods 
studied in silico 
Supplementary Table S6. List of 17 genes manually removed from the multivariate list in silico 
Supplementary Table S7. List of 29 genes added to the candidate list  
Supplementary Table S8. Details of the 100 probe NanoString code set used in TransATAC 
Supplementary Table S9. Hazard ratios, confidence intervals and p-values for the 92 genes assessed 
in TransATAC in univariate analyses 
Supplementary Table S10. Demographics of TransATAC cohort 
Supplementary Table S11. Demographics of POLAR cohort 
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; PgR = progesterone receptor; NPI 
= Nottingham Prognostic Index; AI = aromatase inhibitor; RMH = LUH = ; POLAR = molecular 
Predictors Of early versus LAte Recurrence in ER+ breast cancer. * denotes matching criteria. 
Figure 1. Flowchart of gene signature derivation in silico and in TransATAC cohort.  
QC = Quality control; ATAC= Arimidex, Tamoxifen, Alone or in Combination. 
Figure 2. CONSORT diagram of the availability of samples for analysis from the (a) ATAC trial and (b) 
POLAR collection of samples.  
Supplementary Figure 1. Forest plot of hazard ratios and confidence intervals for the 92 genes 
assessed in TransATAC in univariate analyses. * denotes significance. 
Supplementary Figure 2. Hazard ratios and odds ratios for the 10-year signature genes in TransATAC 
and POLAR respectively  
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Figure 1. Flowchart of gene signature derivation in silico and in TransATAC cohort.  
QC = Quality control; ATAC= Arimidex, Tamoxifen, Alone or in Combination. 
 
 
 
 
 
Figure 2. CONSORT diagram of the availability of samples for analysis from the (a) ATAC trial and 
(b) POLAR collection of samples.  
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Variable 10-year signature Early signature Late signature 
ALDH1A1   -0.194 
ANP32E 0.143 0.010 0.083 
CRABP2 0.084 0.207  
CXCL12  -0.183  
CXCR4 0.142  0.056 
EGFR   -0.030 
ELF5 -0.046 -0.001  
FGF2 -0.178  -0.232 
IGF1 -0.029 -0.017  
IGJ -0.086 -0.037 -0.030 
IL6ST  -0.044  
LINC00341 -0.463 -0.362 -0.392 
LRRC48  -0.104  
MMP9 0.043  0.064 
MPZL1 0.276 0.066 0.043 
NUSAP1 0.088 0.065  
PBX1 0.159  0.375 
PDZK1 -0.011  -0.063 
PGR  -0.073  
PRC1  0.019  
RGL1 -0.429 -0.166 -0.161 
RRM2 0.077 0.124  
SFRP1 -0.017  -0.278 
STC2 -0.087 -0.068  
TNF -0.029  -0.026 
ZEB2   -0.138 
CTS 0.514 0.409 0.516 
 
Table 1. Variables and corresponding beta-coefficients of the time-dependent 10-year, early and 
late signatures. 
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Table 2. HRs (95% CI), LRχ², p-values and c-indices for CTS, 10-year, early and late signatures in 
TransATAC validation cohort.  
Both univariate and multivariate analyses are presented for years 0 to 10, years 0 to 5, and years 5 
to 10 separately. Likelihood ratio test based on Cox proportional hazard models for univariate and 
multivariate analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS = clinical 
treatment score; LR = likelihood ratio; HR = hazard ratio; CI = confidence interval. 
 
 
 
Score No. of 
patients 
(relapses
) 
Univariate comparisons Multivariate comparisons: 
CTS+signature vs CTS 
LR
χ² 
p HR (95% 
CI) 
c-
inde
x 
P diff ΔL
Rχ² 
p HR (95% 
CI) 
c-
inde
x 
P diff 
0-10 years 
CTS 
314 (59) 
48
.7 
<0.
001 
2.16 (1.79 
- 2.62) 
0.67
4 
- - - - - - 
10-year 
signature 
28 <0.
001 
1.98 (1.54 
- 2.55) 
0.67
1 
refere
nce 
7.9 0.0
05 
1.49 (1.13 
- 1.96) 
0.70
9 
refer
ence 
Early 
signature 
33
.4 
<0.
001 
2.06 (1.62 
- 2.61) 
0.67
8 
0.334 10.
3 
0.0
01 
1.55 (1.19 
- 2.02) 
0.71
1 
0.48 
Late 
signature 
18
.1 
<0.
001 
1.72 (1.34 
- 2.20) 
0.64
2 
0.000 4.3 0.0
37 
1.33 (1.02 
- 1.74) 
0.7 0.004 
0-5 years 
CTS 
314 (26) 
29 <0.
001 
2.04 (1.53 
- 2.74) 
? - - - - - - 
10-year 
signature 
14
.1 
<0.
001 
2.05 (1.41 
- 2.98) 
0.67
8 
0.833 3.2 0.0
73 
1.46 (0.97 
- 2.19) 
0.71
2 
0.77 
Early 
signature 
14
.9 
<0.
001 
2.00 (1.42 
- 2.81) 
0.67
2 
refere
nce 
2.8 0.0
96 
1.40 (0.95 
- 2.06) 
0.70
5 
refer
ence 
Late 
signature 
8.
9 
0.0
03 
1.77 (1.22 
- 2.57) 
0.64
8 
0.138 1.7 0.1
9 
1.31 (0.87 
- 1.97) 
0.70
5 
0.65 
5-10 years 
CTS 
270 (33) 
19
.8 
<0.
001 
1.84 (1.33 
- 2.54) 
? - - - - - - 
10-year 
signature 
13
.9 
<0.
001 
1.93 (1.37 
- 2.72) 
0.66
3 
0.027 4.8 0.0
28 
1.53 (1.05 
- 2.22) 
0.69
6 
0.14 
Early 
signature 
18
.6 
<0.
001 
2.11 (1.52 
- 2.94) 
0.68
1 
0.091 8 0.0
05 
1.70 (1.19 
- 2.43) 
0.70
8 
0.14 
Late 
signature 
9.
3 
0.0
02 
1.68 (1.21 
- 2.34) 
0.63
6 
refere
nce 
2.7 0.0
99 
1.36 (0.95 
- 1.94) 
0.68
6 
refer
ence 
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Table 3. LRχ² and p-values for CTS and 10-year signature in three groups of POLAR validation set.  
Both univariate and multivariate analyses are presented for years 0 to 10, years 0 to 5, and years 5 
to 10 separately. Likelihood ratio test based on Cox proportional hazard models for univariate and 
multivariate analyses. Differences in likelihood ratio values (ΔLRχ2) were used. POLAR = molecular 
Predictors Of early versus LAte Recurrence in ER-positive breast cancer; CTS = clinical treatment 
score; LR = likelihood ratio. 
 
 
 
POLAR patient 
group 
 Prognostic 
signature 
Significance 
measure 
0-10 
years 
0-5 
years 
5-10 
years 
All POLAR 
patients 
No. of patients 
(relapses) 
 n=422 
(247) 
n=308 
(133) 
n=285 
(114) 
 
CTS 
LRχ2 11.23 22.09 0.90 
p 0.0008 <0.0001 0.34 
10-year 
signature 
LRχ2 12.44 14.59 4.18 
p 0.0004 0.0001 0.041 
CTS+10-year 
signature vs 
CTS 
ΔLRχ2 7.74 7.59 3.58 
p 0.0054 0.0059 0.0586 
Chemotherapy-
treated 
No. of patients 
(relapses) 
 n=170 
(99) 
n=128 
(57) 
n=113 
(42) 
 
CTS 
LRχ2 7.75 15.25 0.11 
p 0.0054 0.0001 0.7437 
10-year 
signature 
LRχ2 7.73 7.41 3.15 
p 0.0054 0.0065 0.08 
CTS+10-year 
signature vs 
CTS 
ΔLRχ2 6.71 5.95 3.12 
p 0.0096 0.0147 0.0773 
Chemotherapy-
naïve 
 
No. of patients 
(relapses) 
 n=252 
(148) 
n=180 
(76) 
n=172 
(72) 
 
CTS 
LRχ2 6.1 10.08 2.19 
p 0.0135 0.0015 0.1387 
10-year 
signature 
LRχ2 5.39 7.26 1.70 
p 0.0202 0.0071 0.19 
CTS+10-year 
signature vs 
CTS 
ΔLRχ2 2.47 2.72 0.82 
p 0.1158 0.0992 0.3647 
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Table 4. HRs (95% CI), LRχ², p-values and c-indices for CTS, 10-year signature, BCI, RS, ROR and 
IHC4 for all and distant recurrences respectively in the TransATAC validation cohort. 
Both univariate and multivariate analyses are presented. Likelihood ratio test based on Cox 
proportional hazard models for univariate and multivariate analyses. Differences in likelihood ratio 
values (ΔLRχ2) were used. AR = all recurrence; DR = distant recurrence; CTS = clinical treatment 
score; BCI = breast cancer index; RS = recurrence score; ROR = risk of recurrence; LR = likelihood 
ratio; HR = hazard ratio; CI = confidence interval. 
All recurrence (N=271, AR= 55) 
 Univariate Multivariate comparison: CTS+signature 
vs CTS 
Score LRχ2 p HR (95% CI) c-
index 
∆LRχ2 p HR (95% CI) c-
index 
CTS 37.4 <0.001 1.94 (1.57 - 
2.40) 
0.664 - - - - 
10-year 
signature 
20.7 <0.001 1.85 (1.42 - 
2.41) 
0.657 5.7 0.017 1.42 (1.07 - 
1.89) 
0.695 
BCI 25.0 <0.001 2.07 (1.54 - 
2.77) 
0.679 9.5 0.002 1.62 (1.19 - 
2.21) 
0.711 
RS 11.1 <0.001 1.52 (1.21 - 
1.91) 
0.607 5.8 0.016 1.35 (1.07 - 
1.71) 
0.683 
ROR 18.3 <0.001 1.77 (1.36 - 
2.31) 
0.650 6.0 0.014 1.42 (1.07 - 
1.87) 
0.700 
IHC4 14.4 <0.001 1.63 (1.28 - 
2.10) 
0.629 7.5 0.006 1.46 (1.12 - 
1.91) 
0.696 
Distant recurrence (N=271, DR= 41) 
 Univariate Multivariate comparison: CTS+signature 
vs CTS 
Score LRχ2 p HR (95% CI) c-
index 
LRχ2 p HR (95% CI) c-
index 
CTS 46.7 <0.001 2.25 (1.79 - 
2.82) 
0.689 - - - - 
10-year 
signature 
26.4 <0.001 2.24 (1.64 - 
3.06) 
0.694 8.5 0.004 1.65 (1.18 - 
2.30) 
0.733 
BCI 34.0 <0.001 2.71 (1.91 - 
3.84) 
0.726 14.5 <0.001 2.03 (1.40 - 
2.95) 
0.754 
RS 10.7 <0.001 1.58 (1.23 - 
2.03) 
0.616 5.1 0.024 1.38 (1.06 - 
1.79) 
0.707 
ROR 21.3 <0.001 2.05 (1.50 - 
2.79) 
0.680 7.5 0.006 1.58 (1.14 - 
2.21) 
0.736 
IHC4 17.9 <0.001 1.87 (1.41 - 
2.49) 
0.658 9.8 0.002 1.68 (1.22 - 
2.31) 
0.731  
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Supplementary Figure 1. Forest plot of hazard ratios and confidence intervals for the 92 genes 
assessed in TransATAC in univariate analyses. * denotes significance. 
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Supplementary Figure 2. Hazard ratios and odds ratios for the 10-year signature genes in 
TransATAC and POLAR respectively  
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Supplementary Table S10. Demographics of TransATAC cohort 
 
 
 
 
 
 
 
 
 
  
TransATAC 
All Training Validation 
n=948 n=634 n=314 
Age at diagnosis*    
mean, years 64.5 64.1 65.2 
median, years 63.7 63.6 64.2 
Tumour size 
 
 
 
≤2cm 634 427 207 
2-5cm 295 194 101 
>5cm 19 13 6 
Recurrence (all)    
 183 123 59 
Treatment    
Radiotherapy 656 430 226 
Mastectomy 373 262 111 
Grade 
   
1 265 177 88 
2 537 368 169 
3 146 89 57 
Nodal status 
   
node negative 665 441 224 
1-3 positive nodes 199 136 63 
4 or more nodes 84 57 27 
Endocrine Rx 
   
Tamoxifen 464 301 163 
AI 484 333 151 
24 
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RMH LUH POLAR (RMH+LUH) 
Case Control Total Case Control Total Case Control Total 
114 105 219 133 70 203 247 175 422 
Age at 
diagnosis* 
         
mean, years 56 58 57 62 60 61 59 58 59 
median, years 54 58 56 61 58 61 58 58 58 
range, years 
29 - 
93 
28 - 88 28 - 93 
35 - 
100 
35 - 87 
35 - 
100 
29 - 
100 
28 - 88 
28 - 
100 
Tumour size 
         
<2cm 
40 
(35%) 
43 
(41%) 
83 
(38%) 
40 
(30%) 
27 
(39%) 
67 
(33%) 
80 
(32%) 
70 
(40%) 
150 
(36%) 
2-5cm 
63 
(55%) 
54 
(51%) 
117 
(53%) 
89 
(67%) 
40 
(57%) 
129 
(64%) 
152 
(62%) 
94 
(54%) 
246 
(58%) 
>5cm 
11 
(10%) 
8 (8%) 19 (9%) 4 (3%) 3 (4%) 7 (3%) 
15 
(6%) 
11 
(6%) 
26 (6%) 
Grade 
         
1 
12 
(11%) 
14 
(13%) 
26 
(12%) 
9 (7%) 
11 
(16%) 
20 
(10%) 
21 
(9%) 
25 
(14%) 
46 
(11%) 
2 
48 
(42%) 
52 
(50%) 
100 
(46%) 
72 
(54%) 
35 
(50%) 
107 
(53%) 
120 
(49%) 
87 
(50%) 
207 
(49%) 
3 
54 
(47%) 
39 
(37%) 
93 
(42%) 
52 
(39%) 
24 
(34%) 
76 
(37%) 
106 
(43%) 
63 
(36%) 
169 
(40%) 
Histological 
subtype          
IDC 
80 
(70%) 
75 
(71%) 
155 
(71%) 
104 
(78%) 
55 
(79%) 
159 
(78%) 
184 
(74%) 
130 
(74%) 
314 
(74%) 
ILC 
22 
(19%) 
18 
(17%) 
40 
(18%) 
27 
(20%) 
15 
(21%) 
42 
(21%) 
49 
(20%) 
33 
(19%) 
82 
(19%) 
other 
12 
(11%) 
12 
(11%) 
24 
(11%) 
2 (2%) 0 (0%) 2 (1%) 
14 
(6%) 
12 
(7%) 
26 (6%) 
Nodal status 
         
node negative 
60 
(53%) 
56 
(53%) 
116 
(53%) 
42 
(32%) 
29 
(41%) 
71 
(35%) 
102 
(41%) 
85 
(49%) 
187 
(44%) 
1-3 positive 
nodes 
25 
(22%) 
34 
(32%) 
59 
(27%) 
54 
(41%) 
31 
(44%) 
85 
(42%) 
79 
(32%) 
65 
(37%) 
144 
(34%) 
4 or more 
nodes 
29 
(25%) 
15 
(14%) 
44 
(20%) 
37 
(28%) 
10 
(14%) 
47 
(23%) 
66 
(27%) 
25 
(14%) 
91 
(22%) 
PgR 
         
Negative 5 (4%) 7 (7%) 12 (5%) 
25 
(19%) 
9 
(13%) 
34 
(17%) 
30 (%) 16 (%) 
46 
(11%) 
Positive 
20 
(18%) 
23 
(22%) 
43 
(20%) 
102 
(77%) 
56 
(80%) 
158 
(78%) 
122 
(%) 
79 (%) 
201 
(48%) 
Unknown 
89 
(78%) 
75 
(71%) 
164 
(75%) 
6 (5%) 5 (7%) 11 (5%) 95 (%) 80 (%) 
175 
(41%) 
NPI category* 
         
<3.4 
25 
(22%) 
26 
(25%) 
51 
(23%) 
15 
(11%) 
13 
(19%) 
28 
(14%) 
40 
(16%) 
39 
(22%) 
79 
(19%) 
3.4-5.4 
49 
(43%) 
50 
(48%) 
99 
(45%) 
77 
(58%) 
42 
(60%) 
119 
(59%) 
126 
(51%) 
92 
(53%) 
218 
(52%) 
>5.4 
40 
(35%) 
29 
(28%) 
69 
(32%) 
41 
(31%) 
15 
(21%) 
56 
(28%) 
81 
(33%) 
44 
(25%) 
125 
(30%) 
Endocrine 
         
26 
 
Supplementary Table S11. Demographics of POLAR cohort 
 
Supplementary methods 
Patient cohorts 
In silico cohort: 102 duplicate samples that were originally published in GSE6532 and subsequently 
reanalysed under GSE17705 were included in our cohort only once. The ER status of samples in 
GSE6532, GSE9195 and GSE17705 cohorts were defined in the original publications by 
immunohistochemistry. For GSE26971, probe intensity of 205225_at (ESR1) was used with the cut-
off of 1000 also used in the original publication resulting in the removal of 7 samples from 
GSE26971. The HER2 status in all four cohorts was defined by using HER2 probe intensity 
(216836_s_at) with the cut-off of 6000. Forty-four samples were found to be HER2-positive by this 
criterion and subsequently removed from the cohort. In the 0-10 year follow-up period 741 samples 
had 168 DMFS events; the 318 samples with RFS data available had 83 relapses recorded. Nodal 
status was available for 696 samples. 
 
Analytic procedures 
For POLAR archival formalin fixed paraffin-embedded (FFPE) tissue blocks from either surgical 
excision specimens or core biopsies were identified. For patients who had been treated with 
neoadjuvant therapy, the diagnostic core was used for analysis. Oestrogen-receptor (ER), 
progesterone receptor (PgR) and HER2 status were determined from histopathology reports at 
diagnosis. For patients in whom HER2 status was unknown at the original diagnosis, HER2 staining 
was performed initially by immunohistochemistry (IHC) (graded from 0 to 3+) with confirmation of 
HER2 2+ tumours by in situ-hybridization (D-DISH). If tumours were subsequently identified as HER2-
positive, they were excluded from the cohort. 
 
Statistical methods 
For the in silico study raw expression data of 22,277 probes was MAS5.0 normalized on a platform 
basis using the justMAS function in the simpleaffy R library to a mean target intensity of 600, 
without background correction. The two normalised datasets were then merged. Cross-cohort batch 
Therapy* 
Tamoxifen only 
80 
(70%) 
72 
(69%) 
152 
(69%) 
96 
(72%) 
50 
(71%) 
146 
(72%) 
176 
(71%) 
122 
(70%) 
298 
(71%) 
Any AI 
34 
(30%) 
33 
(31%) 
67 
(31%) 
37 
(28%) 
20 
(29%) 
57 
(28%) 
71 
(29%) 
53 
(30%) 
124 
(29%) 
Chemotherapy* 
         
No 
54 
(47%) 
49 
(47%) 
103 
(47%) 
94 
(71%) 
55 
(79%) 
149 
(73%) 
148 
(60%) 
104 
(59%) 
252 
(60%) 
Yes 
60 
(53%) 
56 
(53%) 
116 
(53%) 
39 
(29%) 
15 
(21%) 
54 
(27%) 
99 
(40%) 
71 
(41%) 
170 
(40%) 
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effects were corrected using the COMBAT (sva R package, Surrogate Variable Analysis) empirical 
Bayes method (Johnson et al, 2007), directly removing known batch effects. Expression probes that 
had a <10% intensity of all probes were removed. Seventy-five genes had no corresponding probes 
in the assay, 510 genes had 933 probes associated in the assay, of which for each gene the highest 
variance was selected. Cox Proportional Hazard was used with both continuous and median split 
expression to identify significantly prognostic genes. Hazard ratios and Odds ratios were derived 
from the standard deviation of the Cox-model regression coefficient. Analyses were performed in 
the early, late and 10 year time periods with distant metastasis-free survival (DMFS) and relapse-free 
survival (RFS) as endpoints respectively. Statistically significant genes in univariate analyses were 
entered into multivariate Cox proportional hazards models. 
In TransATAC the 92 genes were evaluated in the 948 sample set by continuous univariate Cox 
Proportional Hazard, genes significant at p<0.05 were taken forward for signature generation. For 
this, the 948 patients were randomly split into 2/3 training (n=634) and 1/3 validation (n=314) sets. 
Number of events were split similarly, nodal status and tumour size were matched between training 
and validation sets. Genes statistically significant in univariate analyses in either early, late or 10-
year periods and clinical treatment score (CTS) were entered into multivariate selection process. 
Elastic net penalised Cox regression was used for feature selection with leave one out cross-
validation. The minimum partial likelihood deviance was estimated for different alpha values. This 
was done by varying the lambda tuning parameter, that controls the overall level of shrinkage. 
Leave-one-out cross-validation of the partial likelihood deviance was used to estimate the best 
lambda. The partial likelihood deviance given alpha and lambda was obtained by getting a 1 model 
to all data except one observation. Then the deviance difference was between all data, and a 
calculation not using the observation left out. This was repeated for all data points. The lambda for 
each alpha was chosen was based on a `one-standard-error' rule. This selects the model with 
deviance one standard error away from the minimum. Alpha was set at 0.2 for all three model 
selections. Composite scores were built using the selected features and the beta-coefficients were 
determined. Beta-coefficients were normalised by dividing the gene standard deviation of the 
training population. 
In POLAR the primary analyses were performed on all POLAR patients for which NanoString data was 
available and passed QC criteria. A control was defined as a patient who did not relapse during 
follow up. Controls were randomly selected according to matching criteria from the remaining 
cohort of patients who did not relapse during follow-up. The four matching criteria used in this study 
were: (i) age at diagnosis (≤50 years, >50 years), (ii) Nottingham Prognostic Index (NPI) category 
(<3.4; 3.4-5.4, >5.4), (iii) type of adjuvant endocrine therapy (tamoxifen only, any aromatase 
inhibitor), (iv) chemotherapy use (yes, no). All parametric unpaired t-tests were performed using 
PRISM software (Version 6.0c). Conditional logistic regression was performed using STATA to test 
whether the 10-year signature, CTS and individual genes were associated with risk of recurrence in a 
non-pairwise fashion. A multivariate conditional logistic regression analysis was performed to see 
whether CTS and the 10-year signature were independent variables in a forward selection manner 
with a 5% significance level in a non-pairwise fashion. A log likelihood test was used to test the 10-
year signature and CTS score in a model provides a better fit than CTS alone with a 5% significance 
level. The two separate hospital cohorts constituting POLAR were also analysed separately, no 
significant difference in the results was found (data not shown). 
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